Concord Biotech Ltd (CONCORDBIO) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Concord Biotech reported stable performance in Q3 FY25, with revenue from operations at INR 244 crores, a 1% increase compared to Q3 FY24. This moderate growth was attributed to customer procurement patterns and upcoming annual tenders for formulations.
- EBITDA for Q3 FY25 reached INR 98 crores, with margins at 40.1%. Profit after tax stood at INR 76 crores, with margins at 31.1%.
- For the nine months of FY25, revenues grew by 10% year-on-year, driven by a 3% rise in API revenues and a substantial 42% increase in formulation revenues.
- The company maintains a positive outlook, aiming for a 25% CAGR growth over the next five years.
- Concord Biotech received the Sustainability Reporting Award from the Institute of Chartered Accountants of India, highlighting its commitment to sustainable and ethical growth.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.